1. LB1530. Clinical Benefit of Oral sabizabulin for Hospitalized Adults with CoVID-19 on Supplemental Oxygen. (15th December 2022) Authors: Gonzales, Tara L; Skarda, Paula; Bird, Thomas G; Schnaus, Michael; Steiner, Mitchell; Skolnick, Alan; Gary Barnette, K; Gordon, Michael S; Sprinz, Eduardo; Rodriguez, Domingo; Rodriguez, Domingo; Kalaydzhiev, Petar; Arabadzhiev, Georgi Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MP27-15 SABIZABULIN HAS BOTH CYTOTOXIC AND CYTOSTATIC ACTIVITY IN PHASE 1B/2 CLINICAL OF MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PROGRESSED ON ANDROGEN RECEPTOR TARGETING AGENTS. (May 2022) Authors: Markowski, Mark; Eisenberger, Mario; Pieczonka, Christopher; Getzenberg, Robert; Rodriguez, Domingo; Barnette, K. Gary; Steiner, MItchell; Saltzstein, Daniel; Antonarakis, Emmanuel; Tutrone, Ronald Journal: Journal of urology Issue: Volume 207(2022)Supplement 5 Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗